中国麻风皮肤病杂志 ›› 2020, Vol. 36 ›› Issue (7): 387-389.doi: 10.12144/zgmfskin202007387

• 论著 • 上一篇    下一篇

司库奇尤单抗治疗中重度斑块型银屑病患者中NLR与PASI值相关性分析

孙杰,王睿,宋翠豪,刘卉莹,黄敏,丁香玉,李承新   

  1. 中国人民解放军总医院第一医学中心，北京，100853
  • 出版日期:2020-07-02 发布日期:2020-07-02
  • 通讯作者: 李承新，E-mail: chengxinderm@163.com

Correlation between NLR and PASI in the patients with moderate to severe plaque psoriasis treated with secukinumab

SUN Jie, WANG Rui, SONG Cuihao, LIU Huiying, HUANG Min, DING Xiangyu, LI Chengxin   

  1. The First Medical Center of PLA General Hospital, Beijing 100853, China
  • Online:2020-07-02 Published:2020-07-02
  • Contact: LI Chengxin, E-mail: chengxinderm@163.com

PDF (PC)

114

摘要： 目的：分析司库奇尤单抗治疗中重度斑块型银屑病时中性粒细胞和淋巴细胞比值(NLR)与PASI值的相关性。方法：2017年4月1日至7月31日中重度斑块型银屑病患者每周皮下注射司库奇尤单抗，治疗4次，随后每4周1次,治疗11次。结果：司库奇尤单抗共治疗中重度斑块型患者22例，PASI评分由治疗前的22.28分下降至2.31分，NLR下降值同PASI下降值具有相关性（r12周=0.504，r24周=0.604，r36周=0.470，r48周=0.454；均P<0.05）。结论：司库奇尤单抗治疗银屑病有效，NLR下降值与PASI下降值呈正相关。

关键词: 银屑病, 中性粒细胞/淋巴细胞比值, 生物制剂

Abstract: Objective: To analyze the correlation between neutrophil to lymphocyte ratio (NLR) and PASI in the patients with moderate to severe plaque psoriasis after treated with secukinumab. Methods: The patients with moderate to severe plaque psoriasis were recruited from April 1st, 2017 to July 31, 2017 and were treated with secukinumab, once a week for 4 times, and then, once every 4 weeks for 11 times. Results: Twenty-two patients were treated with secukinumab. After the treatment, the PASI score decreased from 22.28 to 2.31. There was a positive correlation between the decrease level of NLR and the decrease score of PASI (rw12=0.504，rw24=0.604，rw36=0.470，rw48=0.454；Ps<0.05). Conclusion: Secukinumab is effective in the treatment of the patients with moderate to severe plaque psoriasis and there is a positive correlation between the decrease level of NLR and the decrease score of PASI.

Key words: psoriasis, neutrophil to lymphocyte ratio, biologics